Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT06580002
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Sarcoma
- Gastric Cancer
- Lung Cancer
- Head and Neck Cancer
- Colorectal Cancer
- Ovarian Cancer
- Liver Cancer
- Genitourinary Cancer
- Gynecologic Cancer
- Urinary Bladder Cancer
- Leukemia
- Lymphoid Leukemia
- Myeloma Multiple
- Prostate Cancer
- Pancreas Cancer
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Brain Cancer
- Melanoma
- Mycosis Fungoides
- Kidney Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, Irvine
- Last updated on ClinicalTrials.gov
- July 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.